|
Volumn 69, Issue 3, 2004, Pages 177-178
|
Presenting health risks honestly: Mifepristone, a case in point
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
CLOPIDOGREL;
MIFEPRISTONE;
PARACETAMOL;
SILDENAFIL;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
DIABETES MELLITUS;
DRUG ACTIVITY;
DRUG EXPOSURE;
DRUG FATALITY;
DRUG MARKETING;
DRUG SAFETY;
EDITORIAL;
HEALTH;
HEALTH HAZARD;
HEART DISEASE;
HEART MUSCLE ISCHEMIA;
HUMAN;
INTERPERSONAL COMMUNICATION;
LIVER FAILURE;
MEDICAL INFORMATION;
PREGNANCY;
PREGNANCY TERMINATION;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
STROKE;
SURVIVAL;
VASCULAR DISEASE;
|
EID: 1242328749
PISSN: 00107824
EISSN: None
Source Type: Journal
DOI: 10.1016/j.contraception.2003.11.016 Document Type: Editorial |
Times cited : (1)
|
References (12)
|